VentureBang was informed that recently, Kuoran Biomedical Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Koran Gene”) announced that it has completed tens of millions of RMB in Pre-A round of financing. This round of financing was led by Guosheng Furui, and Jinyun Shanghui served as the financing consultant. The funds will be used to further promote the company’s next-generation pathology technology (NGP) and IVD product application registration reserve layout, and accelerate product launch.
Kuoran Gene is a leading company in the next-generation pathology diagnosis, central nervous system tumor and hepatobiliary tumor in vitro diagnosis products. The company currently has a total of 48+ detection products, and has registered 6 IVD products for registration and reserves, and operates nationwide. It has established 2 CAP-certified independent medical testing laboratories, which can realize accurate detection of early tumor screening, auxiliary diagnosis, intraoperative prediction and monitoring, and postoperative recurrence risk assessment. It has cooperated with more than 500 medical institutions.
Secondly, in-depth cooperation with universities, enterprises, scientific research institutions and tertiary hospitals to realize the transformation and implementation of various achievements, provide high-margin products and profits with in vitro diagnostic reagents (IVD), and further support research and development; at the same time, the in-depth layout is based on multiple fluorescence immunoassays. The next-generation pathological diagnosis of the chemical technology platform has been commercialized. This is completely in line with the entrepreneur’s business philosophy and methodology of ‘potential, market, and affairs’, namely: optimistic about the trend, determine the strategic direction; focus on the market, determine the subdivision; “
The founding team of Kuoran Gene has more than 10 years of experience in the medical field, and has inherent advantages in sales network layout, process management, and cost control. In terms of business layout, Kuoran Gene has formed a unique model of “LDT+IVD, NGP+NGS”.
In the business layout of “LDT+IVD”, Kuoran Gene and clinical experts have fully communicated and deployed dozens of testing products through the LDT model, which not only formed a stable business income, but also laid a channel for IVD products. On the basis of LDT products, the company has selected some products with broad market and great industrialization prospects for registration application. At present, it has the application and registration reserves of 6 IVD products, including HCC7S “7 kinds of microRNA liver cancer auxiliary diagnosis detection kit”, The HCC5R “Assessment Kit for Postoperative Metastasis and Recurrence Risk of Liver Cancer”, etc., have formed technical barriers in IVD products for brain tumors and hepatobiliary tumors.
In addition, Kuoran Gene pioneered the new clinical application of NGP+NGS and deployed the next generation of pathological technologies. Kuoran Gene is an early entry into the NGS market and is used in solid tumors such as brain tumors. The NGS market is increasingly competitive, and as the focus of tumor diagnosis and pathology shifts from targeted therapy to tumor immune microenvironment research, NGS has gradually exposed its deficiencies.
From HE staining, to FISH to immunoomics, pathological diagnosis technology has not yet achieved a subversive breakthrough. Bu Lingbin believes: “Pathological diagnosis will expand from qPCR and NGS to next-generation pathological technologies represented by multiplex fluorescence immunohistochemistry.”
It is worth noting that qPCR has been applied to a certain extent in the pathology department. The NGS kits are not fully covered for the time being. The startup of the machine in the hospital requires a large panel. There is no standard charging model in the hospital, and it is still in the early stage of application. Multiplex fluorescence immunohistochemistry meets the new needs of tumor immune microenvironment research, and there are kits that have obtained registration certificates and a ready-made charging model, which solves many pain points of NGS entering the hospital, and is expected to quickly land in the pathology department.
Multiplex fluorescence immunohistochemistry can be regarded as a technology specially developed for the study of tumor immune microenvironment. Existing research results have shown that multiplex fluorescence immunohistochemistry technology can greatly improve the detection sensitivity, detect low-abundance samples, and achieve a comprehensive and objective analysis of patient tumor immune typing. The tumor microenvironment detection based on multiplex fluorescence immunohistochemistry technology, With a deeper understanding of the tumorigenesis mechanism, it is more likely to predict the response of tumors to immunotherapy, and to accurately screen people who benefit from immunotherapy.
At this stage, the multiplex fluorescence immunohistochemistry technology is generally in the scientific research stage, and Kuoran Gene is expected to become the first domestic enterprise to realize the commercialization of multiplex fluorescence immunohistochemistry technology. Platform, including Opal™ multi-label staining technology, PhenoImager™ HT (formerly Vectra® Polaris) multispectral imaging system and InForm™ image analysis system, and developed 7 detection products.
Next, Kuoran Gene will carry out the registration and certification of the PhenoImager™ HT (formerly Vectra® Polaris) multispectral imaging system, further optimize the InForm™ image analysis system, and output solutions for different diseases to accelerate multiple fluorescence immunohistochemistry The technology has landed in the pathology department.
Bu Lingbin, founder of Kuoran Gene, said: “Koran Gene conducts R&D projects and marketing according to clinical needs, achieving controllable costs, and has received the support of many senior clinical experts. It has strong technical barriers and forward-looking vision, and has proposed NGP (Next Generation Pathology) + NGS (Next Generation Sequencing) technological innovation, which has great potential for future development. More importantly, Kuoran Gene has deployed multiple fluorescence immunology Histochemistry (mIHC), NGS, mass spectrometry and other technology platforms have formed a good ductility and brand effect.”
Zhang Shouzhong, general manager of Guosheng Furui, said: “Koran Gene focuses on the translational research and application of precision medicine, and is committed to providing one-stop molecular diagnostic solutions for multiple application scenarios. Innovative laboratory self-construction projects (LDT) for clinical needs and scientific research needs, providing more application fields for clinical inspection and scientific research, and laying out sales channels for IVD products;
media coverage
A new start-up state in the investment world
Related events
- “Kuoran Gene” announced the completion of tens of millions of yuan in Pre-A round financing, led by Guosheng Furui2022-07-20
- Jiangfeng Bio completed the C round of financing of over 100 million yuan2022-07-12
- ” Yueer Gene ” received US$50 million in Series B financing2022-06-02
- Landing shares completed the 320 million yuan D round of financing led by Ali Health2021-11-10
- Qiuzhen Medical received hundreds of millions of C1 rounds of financing2021-10-08
This article is reprinted from: https://readhub.cn/topic/8hNxNphUf1W
This site is for inclusion only, and the copyright belongs to the original author.